Skip to main navigation Skip to search Skip to main content

P53-dependent upregulation of neutral sphingomyelinase-2: Role in doxorubicin-induced growth arrest

  • Stony Brook University

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Neutral sphingomyelinase-2 (nSMase2) is a ceramide-generating enzyme that has been implicated in growth arrest, apoptosis and exosome secretion. Although previous studies have reported transcriptional upregulation of nSMase2 in response to daunorubicin, through Sp1 and Sp3 transcription factors, the role of the DNA damage pathway in regulating nSMase2 remains unclear. In this study, we show that doxorubicin induces a dose-dependent induction of nSMase2 mRNA and protein with concomitant increases in nSMase activity and ceramide levels. Upregulation of nSMase2 was dependent on ATR, Chk1 and p53, thus placing it downstream of the DNA damage pathway. Moreover, overexpression of p53 was sufficient to transcriptionally induce nSMase2, without the need for DNA damage. DNA-binding mutants as well as acetylation mutants of p53 were unable to induce nSMase2, suggesting a role of nSMase2 in growth arrest. Moreover, knockdown of nSMase2 prevented doxorubicininduced growth arrest. Finally, p53-induced nSMase2 upregulation appears to occur via a novel transcription start site upstream of exon 3. These results identify nSMase2 as a novel p53 target gene, regulated by the DNA damage pathway to induce cell growth arrest.

Original languageEnglish
Article numbere1947
JournalCell Death and Disease
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Dive into the research topics of 'P53-dependent upregulation of neutral sphingomyelinase-2: Role in doxorubicin-induced growth arrest'. Together they form a unique fingerprint.

Cite this